Genetic Variations in Susceptibility to Traumatic Muscle Injuries and Muscle Pain among Brazilian High-Performance Athletes

Abstract

Traumatic muscle injuries (TMIs) and muscle pain (MP) negatively impact athletes’ performance and quality of life. Both conditions have a complex pathophysiology involving the interplay between genetic and environmental factors. Yet, the existing data are scarce and controversial. To provide more insights, this study aimed to investigate the association of single-nucleotide polymorphisms (SNPs) previously linked to athletic status with TMI and MP after exercise among Brazilian high-performance athletes from different sports modalities (N = 345). The impact of important environmental determinants was also assessed. From the six evaluated SNPs (ACTN3 rs1815739, FAAH rs324420, PPARGC1A rs8192678, ADRB2 rs1042713, NOS3 rs1799983, and VDR rs731236), none was significantly associated with TMI. Regarding MP after exercise, ACTN3 rs1815739 (CC/CT vs. TT; adjusted odds ratio (aOR) = 1.90; 95% confidence interval (95%Cl), 1.01–3.57) and FAAH rs324420 (AA vs. AC/CC; aOR = 2.30; 95%Cl, 1.08–4.91) were independent predictors according to multivariate binomial analyses adjusted for age (≥23 vs. <23 years), sex (male vs. female), and tobacco consumption (yes vs. no). External validation is warranted to assess the predictive value of ACTN3 rs1815739 and FAAH rs324420. This could have implications for prophylactic interventions to improve athletes’ quality of life.

1. Introduction

The musculoskeletal system is an intricate framework primarily consisting of the skeletal structure and muscles, while also encompassing ligaments and tendons. It represents the backbone of form, stability, support and movement of the human body [1,2]. However, the function and overall effectiveness of this system can be easily disturbed, mainly by physical injury, causing muscle pain (MP) and potentially impairing the daily activity of individuals [3]. Importantly, MP can manifest as acute (sudden and severe) or chronic (long-lasting) [4,5].

Naturally, the musculoskeletal system has a key role in sports practice [6]. At the highest level of competition (i.e., elite sports), musculoskeletal injuries represent the most common health problem, imposing different levels of impact (both acute and chronic), with some leading to enduring disability [7,8,9]. The prevalence of musculoskeletal lesions in elite athletes is around 80%. Although the specific type and location may vary depending on the sport, muscle injuries are the most frequently observed lesions in this subpopulation, constituting 55% of cases [10]. These lesions comprise strains, sprains, contusions, dislocations, and rupture, with the former and the latter being more prevalent [7]. Consequences of traumatic muscle injuries (TMIs) include the lowering of athletic performance, withdrawal from important competitions, and lifetime disability [9,11]. Moreover, TMI may also affect athletes’ mental health and resilience, and a huge economic burden is associated with diagnosing and treating these lesions [12,13,14,15]. Identifying those at an increased risk for this type of injury and MP after exercise may help tailor prophylactic measures. Thus, a better understanding of the underlying biological mechanisms is required.

Over the last few years, genetic factors, particularly, single-nucleotide polymorphisms (SNPs), have been associated with athletic performance. Their impact on the susceptibility to sports-related lesions is, however, less explored [16,17]. The gene actinin alpha 3 (ACTN3), popularly referred to as the “speed gene,” has been consistently connected to athletic performance through its modulation of sports-related phenotypes, including training adaptation and recovery, as well as the risk of injury [18,19,20]. Fatty acid amide hydrolase (FAAH) encodes for a protein with the same name, which is associated with inflammation, stress, and pain tolerance [21,22,23,24]. PPARG coactivator 1 alpha (PPARGC1A) also encodes a protein with the same name, which is thought to regulate muscle fiber composition and training-induced muscle adaptation [25,26,27,28]. Likewise, adrenoceptor beta 2 (ADRB2) is implicated in several functions concerning the central nervous, cardiovascular, endocrine, and pulmonary systems, all affecting athletic performance [26,29,30]. Nitric oxide synthase 3 (NOS3) is a gene with roles in endothelium activity, endurance performance, and athletes’ susceptibility to lesions [26,31,32]. Vitamin D receptor (VDR) was previously associated with stress fractures among athletes [26,33]. These genes harbor SNPs that, combined with environmental cues, could be involved in both TMI and MP after exercise in the setting of athletic performance. To offer a deeper understanding, a case-control study was designed to evaluate the association between relevant SNPs and the susceptibility to TMI and MP after exercise among high-performance athletes, considering environmental influences.

2. Results

2.1. Characterization of Study Population

This study enrolled 345 Brazilian high-performance athletes with (N = 172) and without (N = 173) TMI. The cohort characterization is provided in Table 1. The enrolled athletes participated in various sports disciplines: 129 from rugby, 104 from soccer, 42 from combat sports, 28 from handball, 25 from water polo, 6 from rowing, 4 from volleyball, and 7 from other sports modalities (Figure 1).

Table 1.

Athletes’ characteristics according to the occurrence of TMI.

Characteristics	Athletes			χ2 p-Value
	With TMI (N = 172) N (%)	Without TMI (N = 173) N (%)	Total (N = 345) N (%)
Age (years) *	25.5 ± 5.9	22.4 ± 4.5	23.9 ± 5.4	<0.001
Sex
Female	49 (28.5)	59 (34.1)	108 (31.3)	0.261
Male	123 (71.5)	114 (65.9)	237 (68.7)
BMI (kg/m2) *	24.8 ± 3.5	24.4 ± 3.4	24.6 ± 3.4	0.294
Tobacco consumption **	11 (6.4)	8 (4.6)	19 (5.5)	0.471
Alcohol consumption **	98 (57.0)	97 (56.1)	195 (56.5)	0.865
Age at sports practice initiation (years)	13.4 ± 6.5	14.3 ± 6.0	13.8 ± 6.2	0.190
Training experience (years)*	11.2 ± 6.6	8.1 ± 5.7	9.7 ± 6.4	<0.001
Training frequency (hours/week) *	13.5 ± 9.0	12.4 ± 6.6	13.0 ± 7.9	0.214
Level of sports competition
School/university	19 (11.0)	25 (14.5)	44 (12.8)	0.343
Professional	153 (89.0)	148 (85.5)	301 (87.2)
MP after exercise	87 (50.6)	53 (30.6)	140 (40.6)	<0.001

* Data presented as mean ± standard deviation. ** Defined as both past and active consumption. Bold values represent significant results (p < 0.05) between TMI groups obtained through the Chi-squared test (χ² p-value) or Fisher’s exact test. Abbreviations: BMI, body mass index; TMI, traumatic muscle injury; MP, muscle pain.

Figure 1.

Status of traumatic muscle injury (TMI) across different sports modalities (N = 345). TMI occurrence among high-performance athletes varies significantly depending on the sports modality (Chi-squared test (χ²), p = 0.002).

2.2. Distribution of SNP Genotypes

The distribution of the evaluated polymorphisms is represented in Table 2. Although the Brazilian population is thought to have considerable ancestral heterogeneity, the genomic ancestry of individuals from different regions in Brazil was found to be more homogeneous than first assumed [34]. The genotype frequencies of the evaluated SNPs in this cohort were compared with the reported distribution by other studies with the Brazilian population. For each study, the overall population was considered, i.e., all individuals with and without the trait of interest. The six SNPs were in Hardy–Weinberg equilibrium (χ², p > 0.05), indicating no significant difference in the frequency distribution of the SNPs’ genotypes compared to the frequency described in the literature involving Brazilians from different country regions [35,36,37,38,39,40].

Table 2.

Genotype frequencies of the evaluated SNPs in the study population (N = 345) and the frequencies reported by previous studies with the Brazilian population.

Polymorphism Genotype	Study Population a			Previous Studies with Brazilian Population			χ2 p-Value
	Genotype Frequency	Failed Genotyping	MAF (MA)	Genotype Frequency	MAF (MA)	Reference b
ACTN3 rs1815739
TT	56 (16.2)	1 (0.3)	40.9 (T)	120 (19.9)	41.9 (T)	[35]	0.313
CT	165 (47.8)			265 (44.0)
CC	123 (35.7)			217 (36.0)
FAAH rs324420
AA	31 (9.0)	1 (0.3)	26.9 (A)	14 (7.0)	25.0 (A)	[36]	0.708
AC	123 (35.7)			72 (36.0)
CC	190 (55.1)			114 (57.0)
PPARGC1A rs8192678
TT	31 (9.0)	2 (0.6)	27.1 (T)	15 (6.0)	25.1 (T)	[37]	0.409
CT	124 (35.9)			94 (38.1)
CC	188 (54.5)			138 (55.9)
ADRB2 rs1042713
AA	69 (20.0)	3 (0.9)	43.4 (A)	8 (11.4)	37.9 (A)	[38]	0.226
AG	159 (46.1)			37 (52.9)
GG	114 (33.0)			25 (35.7)
NOS3 rs1799983
TT	28 (8.1)	1 (0.3)	26.9 (T)	13 (6.1)	23.0 (T)	[39]	0.414
GT	129 (37.4)			73 (34.3)
GG	187 (54.2)			127 (59.6)
VDR rs731236
GG	36 (10.4)	1 (0.3)	34.7 (G)	12 (8.1)	29.7 (G)	[40]	0.271
AG	167 (48.4)			64 (43.2)
AA	141 (40.9)			72 (48.6)

^a The study population was recruited in the State of Rio de Janeiro (southeastern region). ^b The study populations in previous studies on ACTN3 rs1815739, FAAH rs324420, PPARGC1A rs8192678, ADRB2 rs1042713, NOS3 rs1799983, and VDR rs731236 were enrolled in various regions of Brazil [35] and the southeastern [36,37,38], northeastern [39], and northern regions [40] of Brazil. Abbreviations: MA, minor allele; MAF, minor allele frequency; SNPs, single-nucleotide polymorphisms.

2.3. Associations between the SNPs and the Athletes’ Characteristics

No significant statistical differences in the distribution of the SNPs’ genotypes according to the athletes’ characteristics were observed, except for adrenoceptor beta 2 (ADRB2) rs1042713 and vitamin D receptor gene (VDR) rs731236. Specifically, a significant association between ADRB2 rs1042713 and the athletes’ age (≥23 vs. <23 years) was detected (GG vs. GA vs. AA, p = 0.027; GG vs. GA/AA, p = 0.010). Namely, the GG genotype was predominant among those aged 23 years or older, while the A allele genotypes were more common within the younger athletes (61.4% and 53.9%, respectively). The distribution of VDR rs731236 genotypes significantly varied according to tobacco consumption (AA vs. GA/GG, p = 0.040) and the athletes’ sex (AA/GA vs. GG, p = 0.044). Specifically, the G allele genotypes were more predominant among the smokers than the non-smokers (84.2% and 57.5%, respectively). Furthermore, although the GG genotype had almost the same frequency between males and females (52.8% and 47.2%, respectively), the A allele genotypes were mostly present among male athletes (70.8%).

2.4. Associations of the SNPs with TMI and MP after Exercise

In univariable binomial regression analyses, no significant association between the evaluated SNPs and TMI occurrence was observed (p > 0.05). In terms of the athletes’ characteristics, age (≥23 vs. <23 years; odds ratio (OR) = 2.42; 95% confidence interval (95%Cl), 1.57–3.73; p < 0.001) and training experience (≥9 vs. <9 years; OR = 2.41; 95%Cl, 1.56–3.71; p < 0.001) were linked to TMI development. In multivariate binomial regression analyses considering these athletes’ characteristics, no association between the SNPs and TMI was detected (p > 0.05).

Regarding MP after exercise, a significant association was observed for FAAH rs324420. Individuals carrying the AA genotype (A is the minor allele) were two times more prone to MP than those with the C allele (AA vs. AC/CC; OR = 2.20; 95%Cl, 1.04–4.65; p = 0.039). Additionally, a marginal association was detected for ACTN3 rs1815739. Specifically, athletes with the C allele tend to be more susceptible to MP after exercise than TT genotype carriers (CC/CT vs. TT; OR = 1.86; 95%Cl, 1.00–3.48; p = 0.051). Considering the remaining evaluated SNPs, namely, PPARGC1A rs8192678, ADRB2 rs1042713, NOS3 rs1799983, and VDR rs731236, no significant association was identified (p > 0.05). As for the athletes’ characteristics, tobacco consumption was the only predictor of MP after exercise (yes vs. no; OR = 2.65; 95%Cl, 1.02–6.91; p = 0.046). In multivariable binomial regression analyses adjusted for the athletes’ age, sex, and tobacco consumption, FAAH rs324420 and ACTN3 rs1815739 were confirmed to be independent predictors of MP after exercise (Table 3).

Table 3.

Multivariable binomial regression analyses on the susceptibility to muscle pain (MP) after exercise (N = 344) among athletes according to ACTN3 rs1815739 and FAAH rs324420.

Variable	Adjusted OR	95% CI	p -Value
Age (≥23 vs. <23 years 1) *	0.93	(0.60–1.45)	0.756
Sex (male vs. female 1)	0.94	(0.58–1.50)	0.779
Tobacco consumption (yes vs. no 1)	2.74	(1.04–7.27)	0.042
ACTN3 rs1815739 (CC/CT vs. TT 1)	1.90	(1.01–3.57)	0.047
Variable	Adjusted OR	95% CI	p -Value
Age (≥23 vs. <23 years 1) *	0.95	(0.61–1.47)	0.804
Sex (male vs. female 1)	0.92	(0.57–1.48)	0.729
Tobacco consumption (yes vs. no 1)	2.82	(1.07–7.45)	0.037
FAAH rs324420 (AA vs. AC/CC 1)	2.30	(1.08–4.91)	0.031

¹ Reference group. * Cut-off defined based on variable median values. Bold values represent significant results (p < 0.05) obtained through the binomial regression analyses. Abbreviations: CI, confidence interval; OR, odds ratio.

3. Discussion

Beyond environmental factors, particularly, training conditions and nutrition, athletic performance is determined by the individual’s genetic architecture [18]. Indeed, the influence of inherited traits in sports performance has been an attractive research field during the last few decades, with recent studies exploring the genetic contribution underlying sports-related injuries [16]. Given the growing interest in this topic, the present study aimed to evaluate the association between relevant SNPs and the susceptibility to TMI and MP after exercise among high-performance athletes, not dismissing environmental influences.

Starting with TMI, none of the six evaluated SNPs were significantly associated with this condition (p > 0.05). In terms of the athletes’ characteristics, as expected, age and training experience were linked to TMI development. Specifically, older athletes (≥23 vs. <23 years; OR = 2.42; 95%Cl, 1.57–3.73) and those with more training experience (≥9 vs. <9 years; OR = 2.41; 95%Cl, 1.56–3.71) were two times more prone to lesions. Regarding MP after exercise, tobacco consumption was the only predictor. Namely, smokers were almost three times more susceptive to MP than nonsmokers (yes vs. no; OR = 2.65; 95%Cl, 1.02–6.91; p = 0.046). Indeed, the use of tobacco has been demonstrated to have negative repercussions on the musculoskeletal system [41]. Due to direct toxic effects, tobacco can diminish bone mineral content, reduce muscle mass strength, and increase the number of fractures and the risk of MP [41,42]. Thus, the study results are in line with the current evidence. Furthermore, the SNPs ACTN3 rs1815739 (R577X) and FAAH rs324420 (C385A) were found to be independent predictors of MP after exercise according to the multivariate analyses adjusted for the athletes’ age, sex, and tobacco use.

ACTN3 is a sarcomeric protein that anchors actin filaments to the Z-line in fast-twitch type 2 muscle fibers. By generating force at high speed, these fibers promote short and explosive periods of physical activity [43,44]. In addition to muscle performance, α-actinin-3 is also implicated in several metabolic and signaling pathways due to its interaction with multiple macromolecules [45]. The R577X SNP is defined by the substitution of a cytosine (C) to a thymine (T) at nucleotide position 1747. This change (C > T) results in the conversion of an arginine (R allele) to a premature stop codon (X allele) at residue 577, which translates into the expression of a truncated and non-functional protein [26,46,47]. Importantly, TT and CC genotypes had a frequency consistent with that reported in the literature for Brazilian individuals [35]. Carriers of the 577XX genotype (or TT genotype) are known to be deficient in α-actinin-3 and consequently have a lower fast-twitch fiber percentage, meaning lower fast type 2 muscle function [46]. Interestingly, around 18% of healthy white individuals and about 16% of people worldwide have this genotype, and it is more common in the general population than in sprint and power athletes [43,44,48]. As for those with the 577R allele (C allele), the varied expression levels of α-actinin-3 at certain conditions can affect muscle performance differently [48]. Indeed, previous studies suggested that ACTN3 genotypes have the potential to change the functioning of the skeletal muscle through metabolic, structural, or signaling-dependent mechanisms [18,44,49,50]. As expected, these modifications have implications for the overall performance of athletes, as they also affect their risk of TMI and MP [44,51,52]. Power athletes exhibit a higher prevalence of the C allele (associated with α-actinin-3 expression), suggesting that α-actinin-3 is imperative in swiftly optimizing muscle function. In opposition, the TT genotype (related to α-actinin-3 deficiency) is usually found among endurance athletes, indicating that the protein absence might benefit long-distance performance [47]. Taken together, the SNP seems to have a sports modality-related effect. Although the link to sports-related lesions has been explored, the association between ACTN3 SNP and MP remains less understood. The scarce data indicate a protective role of the R577X C allele [51,53]. In the present study, however, athletes carrying the SNP C allele were two times more prone to MP than their counterparts, suggesting a detrimental role. This conflicting result could be explained by the sports modality-related effect of the genetic variant. In this study, the insufficient statistical power prevented stratified analysis based on the sports type, which would also be important given the different distribution of lesions according to sports group [10].

By regulating the neuronal excitability in the amygdala, a brain area that regulates anxiety, FAAH is thought to modulate anxiety-related behavior [54,55]. Also, via the same system, inhibition of FAAH suppresses pathological pain [28,56]. Regarding rs324420, this missense SNP is defined by the substitution of a cytosine (C) to an adenine (A), which results in a higher sensitivity of the encoded protein to proteolytic degradation. In fact, the 385A allele (A allele; minor allele) has been associated with diminished FAAH levels and, thus, higher tolerance to pain [54,55,56]. Interestingly, the same allele was previously linked to better athletic achievements in studies conducted by our research group with rink-hockey and volleyball players [22,23]. In the present study, however, athletes carrying the rs324420 AA genotype were two times more prone to MP after exercise than their counterparts. Given the scarce published data, the mechanisms underlying this finding need to be further dissected. Collectively, FAAH rs324420 may be a potential tool to assess the athletes’ susceptibility to MP and their performance. Whether its implications depend on sports type is a matter of discussion.

Regarding PPARGC1A rs8192678, ADRB2 rs1042713, NOS3 rs1799983, and VDR rs731236, no significant association with TMI or MP was detected in univariable or multivariable analyses (p > 0.05). Worth mentioning is that the distribution of ADRB2 rs1042713 genotypes was different depending on the age group, which was one of the athlete characteristics that was significantly associated with TMI susceptibility. Likewise, VDR rs731236 genotypes were distributed differently depending on tobacco use. Indeed, vitamin D deficiency has been linked to tobacco consumption [57,58]. Whether VDR rs731236 also contributes to this deficiency among the exposed individuals or, inversely, whether the SNP somehow influences tobacco consumption requires further investigation. The VDR rs731236 genotypes were also distributed differently according to the athletes’ sex, which was previously observed in a study conducted by our research group [22]. Taken together and considering the roles of these SNPs, future studies with larger cohort sizes should be conducted to reevaluate the impact of these genetic variants on TMI and MP susceptibility among high-performance athletes.

In terms of the study limitations, the small cohort size and the inability to conduct stratified analysis considering the different sports modalities might have prevented the detection of additional associations. The latter would be important given that each sport has its own requirements and a unique profile of injuries.

4. Materials and Methods

4.1. Athlete Recruitment

For this study, 345 Brazilian athletes with (cases; N = 172) and without (controls; N = 173) TMI were enrolled. The inclusion criteria incorporated athletes aged between 18 and 45 years and whose history of TMI was attributed to sports practice. The recruitment was conducted from March 2018 to December 2019 and involved different sports modalities. All TMI diagnoses were blindly confirmed by two specialized orthopedists. A questionnaire regarding demographic, clinical, sports, and training characteristics was requested of each participant and further checked in the presence of an expert researcher. The questionnaire characteristics were previously defined elsewhere [10].

4.2. SNP Selection

More than 80 genetic determinants have been associated with endurance, power, and/or sports injuries among athletes across different sports modalities [16]. Focusing on the SNPs with roles in muscle function and/or performance, pain, inflammation, and metabolic pathways, the selection of the most suitable SNPs to be evaluated was conducted considering their minor allele frequency (MAF) reported in previous studies with the Brazilian population (an MAF of at least 15% was considered), their functional consequence, and the availability of predesigned TaqMan^TM SNP Genotyping Assays (Applied Biosystems). By applying these criteria, six SNPs were selected, namely, rs1815739 in ACTN3, rs324420 in FAAH, rs8192678 in PPARGC1A, rs1042713 in ADRB2, rs1799983 in NOS3, and rs731236 in VDR.

4.3. Sample Collection, Genomic DNA Extraction, and SNP Genotyping

Genomic deoxyribonucleic acid (DNA) of each athlete was extracted from saliva samples as previously described [59]. DNA concentration and purity were assessed using a Nanodrop^® spectrophotometer (Thermo Scientific^®, Wilmington, DE, USA).

SNP genotyping was performed in a StepOne Plus Real-Time Polymerase Chain Reaction (real-time PCR) system (Applied Biosystems^®, Foster City, CA, USA). The TaqMan^® Allelic Discrimination methodology was employed with the use of predesigned TaqMan^TM SNP Genotyping Assays (Applied Biosystems^®, Foster City, CA, USA). Each PCR reaction was conducted using 2.5 µL of TaqPath^TM ProAmp^TM Master Mix (1×) (Applied Biosystems^®, Foster City, CA, USA); 2.375 µL of sterile water; 0.125 µL of TaqMan^TM SNP Genotyping assay (ACTN3 rs1815739 (C____590093_1_), FAAH rs324420 (C___1897306_10), PPARGC1A rs8192678 (C___1643192_20), ADRB2 rs1042713 (C___2084764_20), NOS3 rs1799983 (C___3219460_20), and VDR rs731236 (C___2404008_10); and 1.0 µL of genomic DNA, in a total volume of 6 µL. The thermal cycling conditions for DNA amplification were described elsewhere [60]. Analysis of DNA amplification was employed by StepOne Software (version 2.3 Applied Biosystems). In each PCR run, negative controls (without DNA) were included to assess false positives. A double sampling of 20% of randomly selected DNA samples was conducted and complete concordance was confirmed. The evaluation of genotyping results was made by three researchers engaged in the study but blinded to the demographic, clinical, sports, and training characteristics of the athletes.

4.4. Statistical Analyses

Statistical analyses were performed using IBM^® SPSS^® Statistics software package version 28.0.0.0 (IBM Corp., Armonk, NY, USA, Released 2021). The distribution of the SNPs’ genotypes in the Brazilian population was assessed and the Hardy–Weinberg equilibrium (HWE) was tested employing the Chi-square test (χ²). The Kolmogorov–Smirnov test was used to evaluate the distribution of variables. Associations between the SNPs (considering the additive, recessive, and dominant genetic models) and the athletes’ demographic, clinical, sports, and training factors were assessed using the χ² test for categorical variables, whereas for continuous ones, either the Mann–Whitney U test or the Student’s t-test was employed (for not-normal and normally distributed variables, respectively). The list of factors included the athletes’ age (years), sex (male vs. female), body mass index (BMI; kg/m²), tobacco consumption (yes vs. no), alcohol consumption (yes vs. no), age at sports practice initiation (years), training experience (years), training frequency (hours/week), and the level of sports competition (school/university vs. professional). The athletes’ age (≥23 vs. <23 years), BMI (≥25 vs. <25 kg/m²), age at sports practice initiation (≥14 vs. <14 years), training experience (≥9 vs. <9 years), and training frequency (≥12 vs. <12 h/week) were also assessed as nominal variables. These variables’ categories were defined based on the median value, as they were not normally distributed (Kolmogorov–Smirnov test, p < 0.05).

Univariable binomial regression analyses were performed to identify SNPs associated with the occurrence of TMI and MP after exercise. In these analyses, a p-value higher than 0.05 but lower than 0.06 was considered marginally significant. Focusing on the relevant SNPs, multivariable binomial regression analyses were conducted, adjusting for the athletes’ age, sex, and other factors significantly linked to the respective trait (TMI and MP after exercise) in the univariable binomial regression analyses.

5. Conclusions

In this case-control study, six SNPs previously linked to athletic performance and with roles in muscle function and/or performance, pain, inflammation, and metabolic pathways were evaluated regarding their impact on the susceptibility for TMI and MP after exercise among Brazilian high-performance athletes across various sports modalities. Although no significant association between the SNPs and TMI was observed, ACTN3 rs1815739 and FAAH rs324420 were found to be independent predictors of MP after exercise. While additional studies are required to replicate and validate the study findings in larger populations that are not primarily based in Brazil, these polymorphisms might constitute useful and valuable biomarkers for personalized training programs to not only optimize performance but also improve the quality of life of athletes. Furthermore, studies focusing on the specific sports modalities are encouraged given that each sport possesses different requirements that might influence the relevance of these SNPs.

Author Contributions

Conceptualization, J.A.P. and R.M.; formal analysis, V.T. and R.M.; funding acquisition, V.T., B.V.N., L.R.L., J.A.P. and R.M.; investigation, I.S.M., V.T. and B.V.N.; methodology, I.S.M., V.T., B.V.N., L.R.L., R.A.G., J.A.M.G. and J.A.P.; resources, J.A.P. and R.M.; supervision, J.A.P. and R.M.; writing—original draft, I.S.M., V.T., B.V.N. and L.R.L.; writing—review and editing, I.S.M., V.T., B.V.N., L.R.L., J.A.P. and R.M. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Instituto Nacional de Traumatologia e Ortopedia (protocol 2.455.630/2017).

Informed Consent Statement

Prior to participation, the recruited athletes signed a written informed consent.

Data Availability Statement

Data will be made available on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Funding Statement

This research was funded by the Fundação para a Ciência e Tecnologia (FCT), the Portuguese League Against Cancer (NRNorte), the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES PrInt- Ficruz), the Carlos Chagas Filho Foundation for Research Support of Rio de Janeiro State (FAPERJ), the National Council for Scientific and Technological Development (CNPq), and the Portuguese Institute of Oncology of Porto (IPO Porto). V.T. is a PhD scholarship holder (grant reference: 2020.08969.BD) supported by the FCT and co-financed by European Social Funds (FSE) and national funds of MCTES. B.V.N. is a research fellow (grant number LPCC-NRN2023-BVN) supported by the Portuguese League Against Cancer (NRNorte). L.R.L. is a PhD scholarship holder supported by CAPES PrInt- Ficruz. J.A.P. is supported by FAPERJ and CNPq. R.M. is supported by IPO Porto (CI-IPOP-22-2015).